146 related articles for article (PubMed ID: 23651535)
1. Community perceptions on the secondary health benefits established by malaria vaccine trials (RTS,S phase 2 and phase 3) at the Korogwe site in North Eastern Tanzania.
Liheluka EA; Lusingu JP; Manongi RN
Malar J; 2013 May; 12():157. PubMed ID: 23651535
[TBL] [Abstract][Full Text] [Related]
2. Community perceptions of malaria and vaccines in two districts of Mozambique.
Bingham A; Gaspar F; Lancaster K; Conjera J; Collymore Y; Ba-Nguz A
Malar J; 2012 Nov; 11():394. PubMed ID: 23186030
[TBL] [Abstract][Full Text] [Related]
3. Community perceptions of a malaria vaccine in the Kintampo districts of Ghana.
Febir LG; Asante KP; Dzorgbo DB; Senah KA; Letsa TS; Owusu-Agyei S
Malar J; 2013 May; 12():156. PubMed ID: 23651533
[TBL] [Abstract][Full Text] [Related]
4. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
[TBL] [Abstract][Full Text] [Related]
5. Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya.
Ojakaa DI; Ofware P; Machira YW; Yamo E; Collymore Y; Ba-Nguz A; Vansadia P; Bingham A
Malar J; 2011 May; 10():147. PubMed ID: 21624117
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
[TBL] [Abstract][Full Text] [Related]
7. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
8. Stakeholders' opinions and questions regarding the anticipated malaria vaccine in Tanzania.
Mtenga S; Kimweri A; Romore I; Ali A; Exavery A; Sicuri E; Tanner M; Abdulla S; Lusingu J; Kafuruki S
Malar J; 2016 Apr; 15():189. PubMed ID: 27048260
[TBL] [Abstract][Full Text] [Related]
9. Community perception on biomedical research: A case study of malariometric survey in Korogwe District, Tanga Region, Tanzania.
Massawe IS; Lusingu JP; Manongi RN
BMC Public Health; 2014 Apr; 14():385. PubMed ID: 24755404
[TBL] [Abstract][Full Text] [Related]
10. Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya.
Achieng F; Rosen JG; Cherop RY; Kariuki S; Hoffman SL; Seder R; Oneko M; Steinhardt LC
Malar J; 2020 Jun; 19(1):226. PubMed ID: 32580719
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
12. Pattern of all-causes and cause-specific mortality in an area with progressively declining malaria burden in Korogwe district, north-eastern Tanzania.
Challe DP; Kamugisha ML; Mmbando BP; Francis F; Chiduo MG; Mandara CI; Gesase S; Abdul O; Lemnge MM; Ishengoma DS
Malar J; 2018 Feb; 17(1):97. PubMed ID: 29482553
[TBL] [Abstract][Full Text] [Related]
13. Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.
McCoy KD; Weldon CT; Ansumana R; Lamin JM; Stenger DA; Ryan SJ; Bardosh K; Jacobsen KH; Dinglasan RR
Malar J; 2021 Apr; 20(1):183. PubMed ID: 33849572
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania.
Mmbando BP; Segeja MD; Msangeni HA; Sembuche SH; Ishengoma DS; Seth MD; Francis F; Rutta AS; Kamugisha ML; Lemnge MM
Malar J; 2009 Jul; 8():165. PubMed ID: 19615093
[TBL] [Abstract][Full Text] [Related]
15. From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
Cohen J; Nussenzweig V; Nussenzweig R; Vekemans J; Leach A
Hum Vaccin; 2010 Jan; 6(1):90-6. PubMed ID: 19806009
[TBL] [Abstract][Full Text] [Related]
16. Assessment of parental perception of malaria vaccine in Tanzania.
Romore I; Ali AM; Semali I; Mshinda H; Tanner M; Abdulla S
Malar J; 2015 Sep; 14():355. PubMed ID: 26383545
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
Agnandji ST; Fernandes JF; Bache EB; Ramharter M
Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
[TBL] [Abstract][Full Text] [Related]
18. Community perceptions on outdoor malaria transmission in Kilombero Valley, Southern Tanzania.
Moshi IR; Ngowo H; Dillip A; Msellemu D; Madumla EP; Okumu FO; Coetzee M; Mnyone LL; Manderson L
Malar J; 2017 Jul; 16(1):274. PubMed ID: 28676051
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
20. Acceptance of a malaria vaccine by caregivers of sick children in Kenya.
Ojakaa DI; Jarvis JD; Matilu MI; Thiam S
Malar J; 2014 May; 13():172. PubMed ID: 24886650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
